Cost-effectiveness of administering oral adsorbent AST-120 to patients with diabetes and advance-stage chronic kidney disease

Hayashino Y, Fukuhara S, Akizawa T, Asano Y, Wakita T, Onishi Y, Kurokawa K

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1016/j.diabres.2010.07.007

Indexing Status
Subject indexing assigned by NLM

MeSH
Administration, Oral; Aged; Carbon /administration & dosage /economics /therapeutic use; Cost of Illness; Cost-Benefit Analysis; Creatinine /metabolism; Diabetes Mellitus, Type 2 /complications /drug therapy /economics; Diabetic Nephropathies /drug therapy /economics /prevention & control; Hemoglobin A, Glycosylated /metabolism; Humans; Kidney Failure, Chronic /mortality /prevention & control; Oxides /administration & dosage /economics /therapeutic use; Quality of Life; Renal Insufficiency, Chronic /complications /drug therapy /prevention & control

AccessionNumber
22010001863

Date bibliographic record published
09/03/2011